Back to search

Agricultural University of Athens

Μελέτη βιοδεικτών σε παθολογικές κλινικές καταστάσεις με προηγμένες βιοαισθητηριακές μεθόδους

Abstract

dc:description

Study of biomarkers in pathological clinical conditions with advanced biosensing methods. School of Applied Biology & Biotechnology Department of Biotechnology Abstract Prostate cancer is one of the most common male malignancies worldwide. In Greece, in 2022, it ranked first among male cancers. For many years, the determination of the prostate-specific antigen (PSA) in the blood has been the established cancer marker for screening every man over age of 45 years. Without underestimating the importance and value of clinical examination, billions are spent on the development of methods for the early and valid detection of this marker. An extensive review of both older and newer techniques used for this purpose, over the decades, has highlighted their costly and time-consuming nature despite the high sensitivity and specificity demonstrated by all these methods.In this study, which was conducted and completed in two phases, an advanced system for the detection of the prostate-specific antigen PSA in human serum was developed. This system based on a cell-based biosensor utilizing the Bioelectrical Identification Assay (BERA), which is potentially portable, low-cost and high-performance, allowing for use anywhere, outside the laboratory, near the patient.In the first phase, an advanced system for the detection of PSA in human serum was developed based on a cell-based biosensor where the cell membrane was modified via electroinsertion of a specific antibody against PSA. Thirty-nine human serum samples were used to validate this biosensor system for PSA detection. The samples were analyzed in parallel with a standard immunoradiometric Assay (IRMA), and an established Electrochemical Immunoassay was used for comparison purposes. In this phase, they were classified into three different PSA concentration ranges (0, <4 and ≥4 ng/mL). Cells modified with electroinsertion of 0.25 μg/mL PSA antibody into their membrane showed a statistically lower response against the higher PSA concentration range (≥4 ng/mL). Furthermore, the cell-based biosensor performed better than the immunosensor in terms of sensitivity and analysis of positive samples containing <4 ng/mL PSA. Despite the preliminary stage of development and the proof-of-principle nature, the cellular biosensor emerges as a promising basis for developing a rapid, cost effective, highly sensitive, and accurate Poin-of-Care (POC) screening system for PSA. During the second phase of experiments the working principle was confirmed, and a pilot clinical evaluation was achieved for a novel biosensor based on bioelectrical impedance methology for PSA detection in human serum. This system utilizes Molecular Identification through Membrane Engineering (MIME) technology combined with the xCELLigence real-time cell analysis platform, using Vero cells as biosensor, with anti-PSA antibodies attach to their membranes via electroporation (electroinsertion). Optimization experiments conducted in this phase determined that 15,000 cells/well was the optimal configuration for achieving the maximum impedance response. The biosensor exhibited specific, concentration-dependent changes in impedance during exposure to standard PSA solutions and demonstrated significant diagnostic capability in differentianing between PSA-positive and PSA-negative human serum samples, based on the established, internationally accepted clinical reference limit (cutoff) of 4 ng/mL. Furthermore, the biosensor provided rapid results within one minute, constituting a substantial advantage over the standard ImmunoradiometricAssay (IRMA) and the chemiluminescence metdod, while demonstrating strong diagnostic agreement. The specificity, sensitivity, and reproducibility of the system enhaced its potential for integration into point-of-care screening workflows. This bioelectrical assay represents one of the fastest PSA detection approaches reported to date and offers a promising solution for reducing prostate cancer overdiagnosis while improving valid and timely clinical decision-making, and consequently clinical patient outcomes. Scientific Area: Biosensors and Biomarkers KEY WORDS: Bioelectric Recognition Assay (BERA); cell-based biosensor; high throughput; impedance; Molecular Identification through Membrane Engineering (MIME); prostate cancer; prostate-specific antigen (PSA)

Degree

thesis:*
Grantor dc:publisher
Agricultural University of Athens
Year dc:date
2026

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Giannakos, Georgios
  • Γιαννακός, Γεώργιος

Subjects

dc:subject × 13

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/60884

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Giannakos, Georgios; Γιαννακός, Γεώργιος. Μελέτη βιοδεικτών σε παθολογικές κλινικές καταστάσεις με προηγμένες βιοαισθητηριακές μεθόδους. Agricultural University of Athens, 2026. http://hdl.handle.net/10442/hedi/60884